Spero Therapeuti Stock Price, News & Analysis

Spero Therapeutics, Inc. (Nasdaq: SPRO) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. According to the company’s public disclosures and press releases, Spero focuses on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections where there is high unmet medical need. The company is classified in Pharmaceutical Preparation Manufacturing within the broader manufacturing sector.

Spero describes itself as a clinical-stage organization, meaning its product candidates are in various stages of clinical development rather than being widely commercialized. Its recent communications emphasize a pipeline centered on serious bacterial infections and rare disease indications, with a particular focus on complicated urinary tract infections (cUTI), including pyelonephritis, and on MDR pathogens.

Core pipeline and therapeutic focus

A central program for Spero is tebipenem pivoxil hydrobromide (tebipenem HBr), described as an investigational oral carbapenem antibiotic. Company releases state that tebipenem HBr is being developed for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, with the goal of providing an oral therapeutic option that can be used outside the hospital setting and potentially reduce the duration of in-patient therapy. Spero has reported that the pivotal Phase 3 PIVOT-PO trial in hospitalized adult patients with cUTI, including pyelonephritis, met its primary endpoint of non-inferiority versus intravenous imipenem-cilastatin on overall response, a composite of clinical cure and microbiological eradication at the test-of-cure visit.

Spero has entered into an exclusive license agreement with GSK for the development and commercialization of tebipenem HBr in all markets except certain Asian territories, where Meiji retains rights. Under this collaboration structure, Spero has conducted key development work, including the PIVOT-PO Phase 3 study, while GSK is responsible for regulatory submissions and commercialization in its licensed territories. Company announcements note that tebipenem HBr has received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the U.S. Food and Drug Administration (FDA.

Beyond tebipenem HBr, Spero has disclosed work on SPR720, described as an investigational, chemically stable phosphate ester prodrug that converts in vivo to SPR719, targeting the ATPase site of DNA gyrase B in mycobacteria. SPR720 was studied as an oral antibiotic candidate for nontuberculous mycobacterium pulmonary disease (NTM-PD), a rare pulmonary infection. The company has stated that the oral development program in NTM-PD was suspended following an interim analysis indicating that a Phase 2a study did not meet its primary endpoint, and that it has discontinued the SPR720 program after reviewing Phase 2a and Phase 1 data in NTM-PD.

Approach to MDR infections and rare diseases

In its public descriptions, Spero emphasizes a focus on MDR bacterial infections and rare diseases with high unmet need. Complicated urinary tract infections, including pyelonephritis, are highlighted as an important health issue often associated with multidrug-resistant pathogens and significant morbidity. By developing tebipenem HBr as an oral carbapenem candidate, Spero aims to address situations where current standard-of-care carbapenems are available only as intravenous therapies. Company materials indicate that an oral option could allow treatment outside the hospital and potentially shorten hospital stays for appropriate patients.

The company’s communications also reference government agency research support for tebipenem HBr. Select studies have been funded in part with federal funds from the U.S. Department of Health and Human Services, the Administration for Strategic Preparedness and Response, and the Biomedical Advanced Research and Development Authority (BARDA) under a specified contract number. These disclosures underscore the public health relevance of Spero’s work in antimicrobial resistance and serious infections.

Collaborations, licensing, and development model

Spero’s business model, as described in its press releases and SEC filings, combines internal clinical development with strategic licensing agreements. For tebipenem HBr, Spero granted GSK an exclusive license for development and commercialization in most territories, while retaining certain development responsibilities under a sub-license arrangement. The company has reported collaboration revenue from GSK and milestone structures tied to development and potential commercial events.

For SPR720, Spero has described a development program aimed at NTM-PD, a rare pulmonary disease, with a mechanism targeting DNA gyrase B in mycobacteria. Following a Phase 2a interim analysis and subsequent data review, Spero has communicated that it suspended and then discontinued this program, and has indicated that it has been determining or has determined next steps in light of the data.

Capital markets and corporate structure

Spero Therapeutics’ common stock is listed on The Nasdaq Global Select Market under the symbol SPRO, as noted in its SEC filings. The company uses equity-based compensation plans, including a 2017 Stock Incentive Plan and a 2019 Inducement Equity Incentive Plan, to grant restricted stock units and other awards, particularly to new employees as inducement grants under Nasdaq Listing Rule 5635(c)(4). Shareholders have approved amendments to increase the share reserve under the 2017 plan, reflecting ongoing use of equity incentives in Spero’s capital structure.

SEC filings and earnings releases show that Spero generates revenue primarily from grant funding and collaboration revenue related to its agreements, including with GSK, rather than from commercial product sales. The company reports research and development expenses associated with its clinical programs, general and administrative expenses, and periodic net losses typical of clinical-stage biopharmaceutical companies. Spero’s public statements include estimates of cash runway based on cash, cash equivalents, and expected milestone payments, but these estimates are time-specific and detailed figures are provided in its periodic SEC reports.

Regulatory and clinical milestones

Spero’s disclosures highlight several key clinical and regulatory milestones for tebipenem HBr. The PIVOT-PO Phase 3 trial was stopped early for efficacy after a pre-specified interim analysis by an Independent Data Monitoring Committee, with no new safety concerns identified beyond prior experience with tebipenem. The company and GSK have reported that trial results were presented as late-breaking data at the IDWeek medical conference and that GSK has pursued or plans to pursue regulatory filings with the FDA, including a resubmission of a New Drug Application (NDA) for tebipenem HBr for cUTI, including pyelonephritis.

According to Spero’s announcements, the NDA resubmission by GSK to the FDA for tebipenem HBr for cUTI, including pyelonephritis, has occurred and is supported by the successful PIVOT-PO Phase 3 trial. The resubmission triggers a milestone payment to Spero under the license agreement. Spero has also noted that tebipenem HBr has received QIDP and Fast Track designations, which are regulatory designations intended to facilitate the development and review of antibacterial products addressing serious or life-threatening infections.

Headquarters and governance

Spero Therapeutics states that it is headquartered in Cambridge, Massachusetts. SEC filings list its common stock as registered under Section 12(b) of the Exchange Act and traded on The Nasdaq Global Select Market. The company holds annual meetings of stockholders where directors are elected, independent auditors are ratified, and executive compensation and equity plan amendments are submitted for advisory or binding votes. These governance actions are documented in its current reports on Form 8-K, including details of stockholder voting results and plan amendments.

Position within the biopharmaceutical industry

Within the pharmaceutical preparation manufacturing industry, Spero positions itself as a company focused on antibacterial drug development and rare disease indications rather than broad primary care markets. Its emphasis on MDR bacterial infections and cUTI, including pyelonephritis, aligns with public health concerns about antimicrobial resistance and the need for new therapeutic options. The company’s reliance on collaborations, grant funding, and regulatory designations reflects a development strategy tailored to high-need, specialized infectious disease areas.

Key points for investors and observers

• Spero Therapeutics is a clinical-stage biopharmaceutical company focused on novel treatments for rare diseases and MDR bacterial infections with high unmet need.
• The company’s lead program, tebipenem HBr, is an investigational oral carbapenem antibiotic in late-stage development for complicated urinary tract infections, including pyelonephritis.
• Spero has licensed tebipenem HBr to GSK for development and commercialization in most territories, while retaining certain development responsibilities and potential milestone and collaboration revenues.
• Another program, SPR720, was investigated for nontuberculous mycobacterium pulmonary disease but has been suspended and then discontinued after clinical data review.
• The company is headquartered in Cambridge, Massachusetts and its common stock trades on The Nasdaq Global Select Market under the symbol SPRO.
• Spero reports grant revenue, collaboration revenue, research and development expenses, and general and administrative expenses in its periodic SEC filings, and has described cash runway expectations based on cash balances and milestone payments.
• Government agencies, including BARDA and other components of the U.S. Department of Health and Human Services, have provided partial funding support for tebipenem HBr research under a specified contract.

FAQs about Spero Therapeutics (SPRO)

• What does Spero Therapeutics do?
  Spero Therapeutics is a clinical-stage biopharmaceutical company that focuses on identifying and developing novel treatments for rare diseases and multi-drug resistant bacterial infections with high unmet need, as described in its press releases and public filings.
• What is tebipenem HBr?
  Tebipenem pivoxil hydrobromide (tebipenem HBr) is an investigational oral carbapenem antibiotic being developed by Spero and its partner GSK for the treatment of complicated urinary tract infections, including pyelonephritis. Company communications state that the Phase 3 PIVOT-PO trial met its primary endpoint of non-inferiority versus intravenous imipenem-cilastatin.
• How is Spero working with GSK?
  Spero has granted GSK an exclusive license to develop and commercialize tebipenem HBr in all territories except certain Asian territories. Under this agreement, Spero has conducted specified development activities, including the PIVOT-PO Phase 3 trial, and GSK is responsible for regulatory submissions and commercialization in its licensed markets. Spero reports collaboration revenue and potential milestone payments under this arrangement.
• What happened to SPR720?
  SPR720 was an investigational oral prodrug targeting DNA gyrase B in mycobacteria and was studied for nontuberculous mycobacterium pulmonary disease. Spero has disclosed that the oral development program was suspended after a Phase 2a interim analysis showed the study did not meet its primary endpoint, and later stated that it discontinued the SPR720 program following review of Phase 2a and Phase 1 data.
• Where is Spero Therapeutics headquartered?
  Spero Therapeutics states that it is headquartered in Cambridge, Massachusetts. This location is referenced in multiple company press releases and SEC filings.
• On which exchange does SPRO trade?
  According to Spero’s SEC filings, its common stock is registered under Section 12(b) of the Exchange Act and trades on The Nasdaq Global Select Market under the ticker symbol SPRO.
• How does Spero generate revenue as a clinical-stage company?
  Spero’s financial disclosures indicate that its revenues come from grant funding and collaboration revenue, including revenue related to its license and collaboration agreement with GSK. The company reports research and development and general and administrative expenses and has reported net losses typical of clinical-stage biopharmaceutical companies.
• Has tebipenem HBr received any special FDA designations?
  Yes. Spero and GSK have stated that tebipenem HBr has received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the U.S. Food and Drug Administration, reflecting its focus on serious infections and potential to address unmet medical needs.
• Does Spero receive government support for its research?
  Company announcements note that select tebipenem HBr studies have been funded in part with federal funds from the U.S. Department of Health and Human Services, the Administration for Strategic Preparedness and Response, and BARDA under a specified contract number.
• Is Spero Therapeutics a commercial-stage company?
  Spero describes itself as a clinical-stage biopharmaceutical company. Its public financial information indicates that it does not rely on broad commercial product sales but instead on grants and collaboration revenue while it advances its pipeline through clinical development.